October 3, 2017 - By Hazel Jackson
Plug Power Inc. is a provider of alternative energy technology focused on the design, development, commercialization and manufacture of hydrogen fuel cell systems used for the industrial off-road market and the stationary power market. The company has market cap of $625.69 million. The Company’s product line includes GenKey, GenDrive, GenFuel, GenCare and ReliOn. It currently has negative earnings. GenKey offers solutions to clients transitioning their material handling vehicles to fuel cell power.
Bvf Inc decreased Concert Pharmaceuticals Inc (CNCE) stake by 20.53% reported in 2017Q2 SEC filing. Bvf Inc sold 479,714 shares as Concert Pharmaceuticals Inc (CNCE)’s stock rose 44.41%. The Bvf Inc holds 1.86 million shares with $25.90M value, down from 2.34M last quarter. Concert Pharmaceuticals Inc now has $341.67 million valuation. The stock increased 2.10% or $0.31 during the last trading session, reaching $15.06. About shares traded. Concert Pharmaceuticals Inc (NASDAQ:CNCE) has risen 18.70% since October 3, 2016 and is uptrending. It has outperformed by 2.00% the S&P500.
Ratings analysis reveals 100% of Plug Power’s analysts are positive. Out of 2 Wall Street analysts rating Plug Power, 2 give it “Buy”, 0 “Sell” rating, while 0 recommend “Hold”. The lowest target is $3.0 while the high is $3.0. The stock’s average target of $3 is 9.09% above today’s ($2.75) share price. PLUG was included in 2 notes of analysts from December 6, 2016. Rodman & Renshaw initiated Plug Power Inc (NASDAQ:PLUG) rating on Tuesday, December 6. Rodman & Renshaw has “Buy” rating and $3.0 target. On Thursday, April 6 the stock rating was maintained by FBR Capital with “Outperform”.
Analysts await Plug Power Inc (NASDAQ:PLUG) to report earnings on November, 6. They expect $-0.03 earnings per share, up 57.14% or $0.04 from last year’s $-0.07 per share. After $-0.10 actual earnings per share reported by Plug Power Inc for the previous quarter, Wall Street now forecasts -70.00% EPS growth.
Eam Investors Llc holds 0.1% of its portfolio in Plug Power Inc for 296,988 shares. Archford Capital Strategies Llc owns 1,847 shares or 0.06% of their US portfolio. Moreover, Mount Lucas Management Lp has 0.06% invested in the company for 150,000 shares. The Connecticut-based Manatuck Hill Partners Llc has invested 0.03% in the stock. Wealthtrust Axiom Llc, a Pennsylvania-based fund reported 35,000 shares.
The stock increased 5.36% or $0.14 during the last trading session, reaching $2.75. About shares traded. Plug Power Inc (PLUG) has risen 11.11% since October 3, 2016 and is uptrending. It has underperformed by 5.59% the S&P500.
Bvf Inc increased Pieris Pharmaceuticals Inc stake by 1.57 million shares to 3.49 million valued at $17.67M in 2017Q2. It also upped Cti Biopharma Corp stake by 4.12M shares and now owns 8.60M shares. Oncomed Pharmaceuticals Inc (NASDAQ:OMED) was raised too.
Among 8 analysts covering Concert Pharmaceuticals (NASDAQ:CNCE), 7 have Buy rating, 0 Sell and 1 Hold. Therefore 88% are positive. Concert Pharmaceuticals had 14 analyst reports since August 12, 2015 according to SRatingsIntel. The firm has “Buy” rating given on Wednesday, August 9 by H.C. Wainwright. Brean Capital initiated it with “Buy” rating and $21 target in Wednesday, August 12 report. The rating was maintained by H.C. Wainwright on Monday, September 18 with “Buy”. JMP Securities maintained Concert Pharmaceuticals Inc (NASDAQ:CNCE) rating on Wednesday, March 9. JMP Securities has “Market Outperform” rating and $24 target. On Monday, November 9 the stock rating was downgraded by UBS to “Neutral”. Roth Capital maintained Concert Pharmaceuticals Inc (NASDAQ:CNCE) on Tuesday, September 22 with “Buy” rating. The company was maintained on Tuesday, September 22 by TH Capital. The firm has “Buy” rating given on Wednesday, September 9 by Aegis Capital. The firm has “Buy” rating by Aegis Capital given on Thursday, June 29. The rating was initiated by Stifel Nicolaus with “Buy” on Friday, July 1.
Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our daily email newsletter.